A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

NCT04209725 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Closed due to slow enrollment

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: CPX-351
DRUG: Quizartinib

Sponsor

SCRI Development Innovations, LLC